Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

Biopharmaceutical benchmarks—2003

Nature Biotechnology volume 21, pages 865–870 (2003)Cite this article

An Erratum to this article was published on 01 November 2003

Since 2000, over a quarter of all new drugs approved have been biopharmaceuticals.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Number of approved biopharmaceuticals in six major markets.

©Rebecca Henretta

Figure 2: Biotechnology medicines by therapeutic category.

©Rebecca Henretta

Figure 3: The number of biopharmaceuticals in clinical trials—2002 versus 2000.

©Rebecca Henretta

References

  1. Walsh, G. Biopharmaceutical benchmarks. Nat. Biotechnol. 18, 831–833 (and associated 6 page pullout supplement) (2000).

    Article  CAS  Google Scholar 

  2. Holmer, A.F. New biotechnology medicines in development, 2002. (Pharmaceutical Research and Manufacturers of America, Washington, D.C.) http://www.phrma.org/publications/publications//2002-10-21.601.pdf (October 2002).

  3. Robinson, K. An industry comes of age. Biopharm Int. 15, (11) 20–24 (2002).

    Google Scholar 

  4. World Health Organization. Hepatitis B Fact Sheet. (WHO, Geneva, Switzerland) http://www.who.int/inf-fs/en/fact204.html (October 2000).

  5. Pfeifer, A. & Verma, I. Gene therapy: promises and problems. Ann. Rev. Genomics Hum. Genet. 2, 177–211 (2001).

    Article  CAS  Google Scholar 

  6. Pouton, C. & Seymour, L. Key issues in non-viral gene delivery. Adv. Drug Del. Rev. 46, 187–203 (2001).

    Article  CAS  Google Scholar 

  7. Lou, D. & Saltzman, W. Synthetic DNA delivery systems. Nat. Biotechnol. 18, 33–37 (2000).

    Article  Google Scholar 

  8. Thompson, L. Human gene therapy. Harsh lessons, high hopes. FDA Consumer Magazine, http://www.fda.gov/fdac/features/2000/500_gene.html, (Sept.–Oct. 2000).

    Google Scholar 

  9. Check, E. Cancer risk prompts US to curb gene therapy. Nature, 422, 7 (2003).

    Article  CAS  Google Scholar 

  10. Akhtar, S. et al. The delivery of antisense therapeutics. Adv. Drug Del. Rev. 44, 3–21 (2000).

    Article  CAS  Google Scholar 

  11. Bouchie, A. Tissue engineering firms go under. Nat. Biotechnol. 20, 1178–1179, 2001.

    Article  Google Scholar 

Download references

Acknowledgements

The author wishes to acknowledge useful comments made by Mark Saifer during the preparation of this article.

Author information

Authors and Affiliations

  1. the Industrial Biochemistry Programme, University of Limerick, Limerick, Ireland

    Gary Walsh

Authors
  1. Gary Walsh
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Walsh, G. Biopharmaceutical benchmarks—2003. Nat Biotechnol 21, 865–870 (2003). https://doi.org/10.1038/nbt0803-865

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0803-865

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing